ARTICLE | Clinical News
BCR/ABL1 Quant Test regulatory update
July 19, 2010 7:00 AM UTC
Asuragen received CE Mark approval in Europe for its BCR/ABL1 Quant Test to aid in the assessment of complete cytogenetic response (CCyR), major molecular response (MMR), minimal residual disease and ...